Christopher Roberson, CRNP
NPI 1184064941 · Adult Health Nurse Practitioner · Baltimore, MD
Enrolled with Medicare as Practitioner - Nurse Practitioner · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1184064941
- Entity type
- Individual
- Primary specialty
- Adult Health Nurse PractitionerPhysician Assistants & Advanced Practice Nursing Providers
- Credential
- CRNP
- Sex
- Male
- Sole proprietor
- No
- License
- R179907 (MD)
Specialties & taxonomies
Physician Assistants & Advanced Practice Nursing Providers
Physician Assistants & Advanced Practice Nursing Providers
Physician Assistants & Advanced Practice Nursing Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure33% of score
12 yrs in NPPES registry
- Profile completeness33% of score
100% of core fields populated
- Practice footprint20% of score
1 documented practice location
- Open Payments transparency13% of score
Has Open Payments disclosures (2024)
Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 9 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Bictegrav/Emtricit/Tenofov Alabrand: Biktarvy | 434 | 55 |
| Dolutegravir/Rilpivirinebrand: Juluca | 98 | 12 |
| Dolutegravir Sodiumbrand: Tivicay | 44 | — |
| Doravirinebrand: Pifeltro | 28 | — |
| Valacyclovir Hclbrand: Valacyclovir | 18 | — |
| Emtricitab/Rilpiviri/Tenof Alabrand: Odefsey | 16 | — |
| Darunavir/Cobicistat |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$56,964 across 175 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2013-06-26
- Last updated
- 2019-05-14
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.